More DCAT Value Chain Insights

In-depth analysis of the critical issues impacting the full spectrum of the pharmaceutical manufacturing value chain.

What have been key developments thus far in 2020 impacting API sourcing, and how may that affect manufacturing networks and supply lines going forward? From plans to increase domestic drug manufacturing to shifts in product mix, DCAT Value Chain...

The FDA finalized a rule last month as part of a plan for the safe importation of drugs from Canada into the US. The rule is part of the Safe Importation Action Plan that was earlier announced by the Trump Administration as part of a strategy to...

The quest for vaccines and treatments against COVID-19 has put the CEOs of certain companies, both large and small, on the industry’s radar. The CEOs of J&J, AstraZeneca, Pfizer, Moderna, and Regeneron Pharmaceuticals are some executives to...

How are biologics faring in terms of new drug approvals? DCAT Value Chain Insights examines biologic-based APIs approved as new molecular entities by the FDA’s Center for Drug Evaluation and Research thus far in 2020 and recent trends. Biologics...

What are the latest developments in upstream and downstream bioprocessing? DCAT Value Chain Insights provides a roundup of CDMO/CMO expansions in biomanufacturing and manufacturing for cell and gene therapies. CDMO/CMO expansions CDMO/CMOs have...

An upcoming DCAT webinar, featuring Graham Lewis, Vice President, Global Pharma Strategy, IQVIA, evaluates the market impact on the COVID-19 pandemic on companies’ pipelines, product launches, and performance and how industry fundamentals and...

What are the key developments from the large pharmaceutical companies’ pipelines expected for later this year? Which new drugs or additional indications for existing drugs have blockbuster potential? DCAT Value Chain Insights takes an inside...

The UK and the European Union (EU) are resuming negotiations this week (September 29 to October 2, 2020) for a deal that would define the UK’s future relationship with the EU post Brexit. As the clock winds down to reach a deal or not, the pharma...